Laszlo Lorand

Q: What Schools Are Affiliated With Laszlo Lorand

Laszlo Lorand is affiliated with the following schools: University of New South Wales, University of Leeds, University of Szeged, University of California, San Diego, Northwestern University, Eötvös Loránd University, University of Chicago

Laszlo Lorand's AcademicInfluence.com Rankings

Laszlo Lorand

Biology

#2932

World Rank

#4567

Historical Rank

Biochemistry

#570

World Rank

#660

Historical Rank

biology Degrees

Download Badge

Biology

Laszlo Lorand's Degrees

PhD Chemistry University of Szeged

Why Is Laszlo Lorand Influential?

(Suggest an Edit or Addition)

According to Wikipedia, Laszlo Lorand was a Hungarian-American biochemist who studied clotting of blood and other bodily fluids. A professor emeritus in cell and molecular biology at the Feinberg School of Medicine, Lorand was a longtime professor in the departments of chemistry and molecular biosciences at Northwestern University before transferring to Northwestern's medical school. Lorand was a co-discoverer of the substance that later became known as factor XIII. He was a member of the National Academy of Sciences.

(See a Problem?)

Laszlo Lorand's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Transglutaminases: crosslinking enzymes with pleiotropic functions (2003) (1391)
Structural origins of fibrin clot rheology. (1999) (498)
Transglutaminases and disease: lessons from genetically engineered mouse models and inherited disorders. (2009) (323)
On the Solubility of Fibrin Clots. (1948) (306)
A filter paper assay for transamidating enzymes using radioactive amine substrates. (1972) (286)
Studies on apyrases. (1961) (271)
Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits (2006) (245)
Factor XIII: Structure, Activation, and Interactions with Fibrinogen and Fibrin (2001) (227)
Human factor XIII: fibrin-stabilizing factor. (1980) (219)
ACTIVATION OF THE FIBRIN STABILIZING FACTOR OF PLASMA BY THROMBIN. (1964) (216)
Diagnostic and genetic studies on fibrin-stabilizing factor with a new assay based on amine incorporation. (1969) (210)
Action of Thrombin in the Clotting of Fibrinogen (1951) (199)
Contribution of fibrin stabilization to clot strength. Supplementation of factor XIII-deficient plasma with the purified zymogen. (1983) (178)
Fibronectin-mediated uptake of gelatin-coated latex particles by peritoneal macrophages (1980) (171)
FIBRINOLIGASE: THE FIBRIN‐STABILIZING FACTOR SYSTEM OF BLOOD PLASMA * (1972) (162)
Calcium-dependent unmasking of active center cysteine during activation of fibrin stabilizing factor. (1974) (159)
Role of the intrinsic transglutaminase in the Ca2+-mediated crosslinking of erythrocyte proteins. (1976) (159)
Amine specificity in transpeptidation. Inhibition of fibrin cross-linking. (1968) (144)
Mechanism of allosteric regulation of transglutaminase 2 by GTP (2006) (140)
Enzymatic basis for the Ca2+-induced cross-linking of membrane proteins in intact human erythrocytes. (1978) (138)
Climate change and the integrity of science. (2010) (137)
The transpeptidase system which crosslinks fibrin by γ-glutamyl-ε-lysine bonds (1968) (131)
Lens transglutaminase and cataract formation. (1981) (130)
DISTRIBUTION OF ADENYL-CYCLASE ACTIVITY IN RABBIT SKELETAL-MUSCLE FRACTIONS. (1965) (116)
Transpeptidation Mechanism in Blood Clotting (1962) (111)
‘Fibrino-Peptide’: New Aspects of the Fibrinogen–Fibrin Transformation (1951) (107)
Specificity of guinea pig liver transglutaminase for amine substrates. (1979) (105)
Viscoelastic properties of fibrin clots. (1973) (104)
Dissociation of the subunit structure of fibrin stabilizing factor during activation of the zymogen. (1974) (102)
Factor XIII (fibrin-stabilizing factor). (1981) (101)
Micromechanical properties of keratin intermediate filament networks (2008) (98)
The action of thrombin on fibrinogen. (1952) (98)
Promotion of thrombin-catalyzed activation of factor XIII by fibrinogen. (1983) (95)
Identification of a Novel Recognition Sequence for Fibronectin within the NH2-terminal β-Sandwich Domain of Tissue Transglutaminase* (2005) (95)
Transamidating enzymes. II. A continuous fluorescent method suited for automating measurements of factor XIII in plasma. (1971) (92)
Regulation of formation of factor XIIIa by its fibrin substrates. (1985) (92)
Fibrin-stabilizing factor (factor XIII). (1976) (90)
Ca2+-related regulatory function of fibrinogen. (1978) (89)
Characterization of the kinetic pathway for fibrin promotion of alpha-thrombin-catalyzed activation of plasma factor XIII. (1991) (87)
Factor XIII and the clotting of fibrinogen: from basic research to medicine (2005) (85)
Complexation of fibronectin with tissue transglutaminase. (1989) (85)
Conserved tryptophan in the core domain of transglutaminase is essential for catalytic activity (2002) (84)
Alpha-chain domain of fibrinogen controls generation of fibrinoligase (coagulation factor XIIIa). Calcium ion regulatory aspects. (1981) (83)
Influence of a natural and a synthetic inhibitor of factor XIIIa on fibrin clot rheology. (1999) (80)
Affinity of human erythrocyte transglutaminase for a 42-kDa gelatin-binding fragment of human plasma fibronectin. (1993) (80)
Accelerated Lysis of Blood Clots (1962) (75)
Interactions of G(h)/transglutaminase with phospholipase Cdelta1 and with GTP. (1999) (75)
Formation of γ‐glutamyl‐ϵ‐lysine bridges between membrane proteins by a Ca2+‐regulated enzyme in intact erythrocytes (1978) (75)
Type-2 plasminogen-activator inhibitor is a substrate for trophoblast transglutaminase and factor XIIIa. Transglutaminase-catalyzed cross-linking to cellular and extracellular structures. (1993) (75)
Hydrolysis of γ:ε Isopeptides by Cytosolic Transglutaminases and by Coagulation Factor XIIIa* (1997) (75)
Cross‐Linking Sites of the Human Tau Protein, Probed by Reactions with Human Transglutaminase (1998) (74)
Transamidase reactions involved in the enzymic coagulation of semen: isolation of -glutamyl- -lysine dipeptide from clotted secretion protein of guinea pig seminal vesicle. (1972) (74)
[59a] Fibrinoligase: The fibrin stabilizing factor system☆ (1970) (73)
Neurodegenerative diseases and transglutaminase. (1996) (73)
Inhibitors of Fibrin Cross-linking : Relevance for Thrombolysis (1966) (69)
Purification of opsonically active human and rat cold-insoluble globulin (plasma fibronectin). (1979) (69)
Titration of Active Centers in Thrombin Solutions. Standardization of the Enzyme (1965) (68)
Transglutaminase as a blood clotting enzyme. (1966) (66)
Lysine as amine donor in fibrin crosslinking (1966) (66)
TITRATION OF THE ACCEPTOR CROSS‐LINKING SITES IN FIBRIN * (1972) (65)
Activation of Blood Coagulation Factor XIII a (1986) (60)
Evolutionary specialization of a tryptophan indole group for transition-state stabilization by eukaryotic transglutaminases (2003) (60)
Studies on the polymerization of fibrin; the role of the globulin: fibrin-stabilizing factor. (1958) (60)
‘Adenosine Triphosphate–Creatine Transphosphorylase’ as Relaxing Factor of Muscle (1953) (59)
SPECIFIC INHIBITORS AND THE CHEMISTRY OF FIBRIN POLYMERIZATION. (1964) (58)
The amino acid composition of bovine prothrombin. (1954) (58)
Fibronectin as a carrier for the transglutaminase from human erythrocytes. (1988) (58)
Sol Sherry Lecture in Thrombosis : research on clot stabilization provides clues for improving thrombolytic therapies. (2000) (57)
Labeling of amine-acceptor cross-linking sites of fibrin by transpeptidation. (1966) (56)
Viscoelastic properties of ligation-inhibited fibrin clots. (1974) (56)
Degradation of transmembrane proteins in Ca2+-enriched human erythrocytes. An immunochemical study. (1983) (56)
A NEW CLASS OF BLOOD COAGULATION INHIBITORS. (1963) (51)
Labeling of epsilon-lysine crosslinking sites in proteins with peptide substrates of factor XIIIa and transglutaminase. (1990) (50)
Modification of shear modulus and creep compliance of fibrin clots by fibronectin. (1981) (50)
A New Haemorrhagic Disorder with Defective Fibrin Stabilization and Cryofibrinogenaemia (1974) (47)
Isolation of transglutaminase-reactive sequences from complex biological systems: a prominent lysine donor sequence in bovine lens. (1992) (47)
Visualization of purified fibronectin-transglutaminase complexes. (1992) (46)
Association of the A subunits of recombinant placental factor XIII with the native carrier B subunits from human plasma. (1993) (46)
Transglutaminase reactions associated with the rat semen clotting system: modulation by macromolecular polyanions. (1977) (46)
Human plasma factor XIII: subunit interactions and activation of zymogen. (1993) (46)
Dansylcadaverine specific staining for transamidating enzymes. (1979) (46)
High-pressure liquid chromatographic procedure for the determination of ϵ-(γ-glutamyl)lysine in proteins (1982) (45)
Catalytic competence of human alpha- and gamma-thrombin in the activation of fibrinogen and factor XIII. (1987) (45)
Haemorrhagic Syndrome of Autoimmune Origin with a Specific Inhibitor against Fibrin Stabilizing Factor (Factor XIII) * (1972) (44)
Introduction: blood coagulation. (1993) (43)
Transamidase kinetics. Amide formation in the enzymic reactions of thiol esters with amines. (1975) (42)
The pancornulins: a group of small proline rich-related cornified envelope precursors with bifunctional capabilities in isopeptide bond formation. (1995) (41)
Inhibition of protein cross-linking in Ca2+-enriched human erythrocytes and activated platelets. (1987) (40)
Transamidating enzymes. I. Rapid chromatographic assays. (1971) (40)
Ester Hydrolysis by Urokinase (1965) (39)
Covalent cross‐linking of secreted bovine thyroglobulin by transglutaminase (2000) (39)
Thrombin-catalyzed hydrolysis of p-nitrophenyl esters. (1962) (39)
Autoimmune antibody (IgG Kansas) against the fibrin stabilizing factor (factor XIII) system. (1988) (39)
Activation of transglutaminase during embryonic development. (1984) (39)
Enzymatic coupling of isoniazid to proteins. (1972) (39)
Inheritance of deficiency of fibrin-stabilizing factor (factor 13). (1970) (38)
Residue Gln-30 of human erythrocyte anion transporter is a prime site for reaction with intrinsic transglutaminase. (1994) (38)
Prolactin-immunoglobulin G complexes from human serum act as costimulatory ligands causing proliferation of malignant B lymphocytes. (1995) (37)
Formation of a 55,000 molecular-weight crosslinked .beta. crystallin dimer in the calcium treated lens. A model for cataract (1985) (36)
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AαIVS4 + 1G>T mutation and an AαGln328 truncation (fibrinogen Keokuk) (2004) (36)
Association of a transglutaminase-related antigen with intermediate filaments. (1995) (35)
Enzymatic basis of membrane stiffening in human erythroyctes. (1979) (34)
Autoimmune antibody in a hemorrhagic patient interacts with thrombin-activated factor XIII in a unique manner. (1999) (34)
New colored and fluorescent amine substrates for activated fibrin stabilizing factor (Factor XIIIa) and for transglutaminase. (1983) (34)
Fibrin Clots (1950) (34)
Difference between type I autoimmune inhibitors of fibrin stabilization in two patients with severe hemorrhagic disorder. (1978) (32)
Cloning and expression of chicken erythrocyte transglutaminase. (1992) (32)
Titration and subunit localization of active center cysteine in fibrinoligase (thrombin-activated fibrin stabilizing fector). (1973) (32)
Assay Method for the “Fibrin-Stabilizing Factor.” (1955) (32)
Sorting-out of acceptor-donor relationships in the transglutaminase-catalyzed cross-linking of crystallins by the enzyme-directed labeling of potential sites (1991) (32)
A pathological inhibitor of fibrin cross-linking. (1968) (32)
Carbohydrate and nitrogen distribution during the activation of purified prothrombin in sodium citrate solution. (1953) (31)
Kinetics of transamidating enzymes. Production of thiol in the reactions of thiol esters with fibrinoligase (1974) (30)
Fibrin-stabilizing Factor (Factor XIII) in the Fetus and the Newborn Infant (1974) (30)
Auto-oscillations in Extracted Muscle Fibre Systems (1956) (30)
Interaction of thrombin and fibrinogen. (1954) (29)
DRPLA aggregation and transglutaminase, revisited (1998) (29)
Modification of human erythrocyte ghosts with transglutaminase. (1975) (29)
Contact with the N Termini in the Central E Domain Enhances the Reactivities of the Distal D Domains of Fibrin to Factor XIIIa(*) (1995) (29)
An immunochemical approach for the analysis of membrane protein alterations in Ca2+-loaded human erythrocytes. (1981) (28)
Storage, ultrastructural targeting and function of toposomes and hyalin in sea urchin embryogenesis (1991) (28)
Cross-linked A alpha.gamma chain hybrids serve as unique markers for fibrinogen polymerized by tissue transglutaminase. (1990) (28)
Intracranial Hemorrhage in Systemic Lupus Erythematosus Associated with an Autoantibody against Factor XIII (2002) (28)
Transglutaminase-catalyzed crosslinking of the Aα and γ constituent chains in fibrinogen (2000) (28)
Chain pairs in the crosslinking of fibrin. (1969) (28)
Intramolecular crosslinking of monomeric fibrinogen by tissue transglutaminase. (1991) (28)
A double-headed Gly-Pro-Arg-Pro ligand mimics the functions of the E domain of fibrin for promoting the end-to-end crosslinking of gamma chains by factor XIIIa. (1998) (28)
Studies on fibrino-peptide. (1952) (27)
The complementary aggregation sites of fibrin investigated through examination of polymers of fibrinogen with fragment E. (1998) (26)
The action of Arvin on Fibrin Stabilizing Factor (factor 13). (1970) (26)
Physiological roles of fibrinogen and fibrin. (1965) (26)
Serum degradation of myelin basic protein with loss of encephalitogenic activity: evidence for an enzymatic process. (1978) (25)
A study on the solubility of fibrin clots in urea. (1948) (25)
Hierarchy of lens proteins requiring protection against heat-induced precipitation by the alpha crystallin chaperone. (1997) (24)
Effects of the calcium-mediated enzymatic cross-linking of membrane proteins on cellular deformability (2005) (24)
Studies on fibrin crosslinking. Nature of the acceptor groups in transpeptidation. (1966) (24)
Transglutaminase-mediated cross-linking of proteins and cell ageing: the erythrocyte and lens models. (1988) (24)
Identification of factor-XIIIa-reactive glutaminyl residues in the propolypeptide of bovine von Willebrand factor. (1995) (24)
Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins. (1998) (23)
New thioester substrates for fibrinoligase (coagulation factor XIIIa) and for transglutaminase. Transfer of the fluorescently labeled acyl group to amines and alcohols. (1981) (22)
Crosslinks in blood: transglutaminase and beyond (2007) (22)
Introduction to clotting and lysis in blood plasma. (1976) (22)
Intramolecular localization of the acceptor cross-linking sites in fibrin. (1969) (22)
FIBRIN‐STABILIZING FACTOR INHIBITORS (1972) (22)
Severe hypodysfibrinogenemia in compound heterozygotes of the fibrinogen AalphaIVS4 + 1G>T mutation and an AalphaGln328 truncation (fibrinogen Keokuk). (2004) (21)
Acceptor-donor relationships in the transglutaminase-mediated cross-linking of lens beta-crystallin subunits. (1987) (20)
Effect of ACTH on biosynthesis of fibrinogen in the rabbit. (1970) (20)
Identification of transglutaminase substrates in inside-out vesicles from human erythrocytes: immunoblotting with anti-dansyl antibody. (1986) (20)
The transpeptidase system which crosslinks fibrin by gamma-glutamyle-episilon-lysine bonds. (1968) (20)
Methods in enzymology. Volume XIX. Proteolytic enzymes. Volume XIX. (1970) (19)
Transglutaminase diseases: from biochemistry to the bedside (2019) (18)
Studies on the biochemistry of contraction and relaxation in glycerinated muscle; the effects of phosphoenolpyruvate. (1957) (17)
Transglutaminase Remembering Heinrich Waelsch (2002) (17)
Biotinylated peptides containing a factor XIIIa or a tissue transglutaminase-reactive glutaminyl residue that block protein cross-linking phenomena by becoming incorporated into amine donor sites. (1992) (16)
Effects of inhibiting transglutaminase during egg fertilization and development. (1994) (16)
Formation of a 55 000-weight cross-linked beta crystallin dimer in the Ca2+-treated lens. A model for cataract. (1985) (15)
Thiolester substrates for transamidating enzymes: studies on fibrinoligase. (1972) (15)
Kinetics of transamidating enzymes. Production of thiol in the reactions of thiol esters with fibrinoligase. (1975) (15)
Separation of activated fibrin-stabilizing factor from thrombin. (1966) (15)
Some comparative aspects of the fibrinogen-fibrin conversion. (1963) (15)
Probing the transglutaminase-mediated, posttranslational modification of proteins during development. (1990) (15)
Properties of purified lens transglutaminase and regulation of its transamidase/crosslinking activity by GTP. (1998) (15)
Transamidating activities of factor XIIIa and of transglutaminases, measured by an ELISA procedure. (1988) (14)
Nucleotide binding by the erythrocyte transglutaminase/Gh protein, probed with fluorescent analogs of GTP and GDP. (2000) (14)
Isonicotinic Acid Hydrazide as an Inhibitor of Transpeptidation: Relevance for Blood Coagulation (1967) (14)
Altered response of stored red cells to Ca2+ stress. (1985) (13)
Selectivity in the post-translational, transglutaminase-dependent acylation of lysine residues. (2009) (13)
Transglutaminase-catalyzed crosslinking of the Aalpha and gamma constituent chains in fibrinogen. (2000) (12)
Cross-linked polymers in the red cell membranes of a patient with Hb-Koln disease. (1987) (11)
Agmatine derivatives as enzyme inhibitors (1964) (11)
Formation of gamma-glutamyl-epsilon-lysine bridges between membrane proteins by a Ca2+-regulated enzyme in intact erythrocytes. (1978) (11)
Immunologic determinants of experimental neurologic autoimmune disease and approaches to the multiple sclerosis problem. (1978) (11)
Proteolytic enzymes. Part C. (1981) (11)
NEW APPROACHES TO OLD PROBLEMS IN THE CLOTTING OF FIBRINOGEN * (1983) (11)
PAPAIN-INDUCED POLYMERIZATION OF FIBRINOGEN. (1964) (11)
Inhibition of Proteolytic Enzymes by Decarboxylated Amino-Acid Derivatives. Effect of Toluenesulphonyl(Tosyl)agmatine (4-Toluenesulphonamidobutylguanidine) on Thrombin and Trypsin (1961) (11)
A simple method for purifying an activator of prothrombin (antihemophilic factor?). (1954) (10)
Inhibition of beta-crystallin cross-linking in the Ca2+-treated lens. (1987) (10)
Enzymatic modifications of human plasma fibronectin in relation to opsonizing activity. (1983) (9)
Interactions of G h y transglutaminase with phospholipase C d 1 and with GTP (1999) (9)
The effect of arginylpeptides on the clotting of fibrinogen with thrombin. (1957) (9)
Nε(γ-glutamyl)lysine crosslinks in the blood clot of the horseshoe crab, Limulus polyphemus (1992) (9)
Degradation of Vimentin in a Cataract Model: The Ca2+‐Treated Lens a (1985) (9)
A transglutaminase-related antigen associates with keratin filaments in some mouse epidermal cells. (1997) (9)
Transglutaminase 2 is essential for adherence of Porphyromonas gingivalis to host cells (2014) (8)
Effect of Fibrinogen and Ca2+ on the Thrombin‐Catalyzed Proteolytic Event That Triggers Activation of Factor XIII (1986) (8)
Fibrin-stabilizing factor inhibitors. 4. Action of some synthetic fibrinoligase inhibitors on human platelet aggregation. (1972) (8)
Ester-hydrolysing Activity of Urokinase Preparations (1964) (8)
Cross-linked Aay chain hybrids serve as unique markers for fibrinogen polymerized by tissue transglutaminase (8)
REGULATION OF FACTOR XIIIa GENERATION BY FIBRINOGEN * (1983) (7)
Cross-linking and proteolysis in Ca2(+)-treated lens homogenates. (1990) (7)
Kinetics of formation of fibrin oligomers. III. Ligation kinetics concurrent with and subsequent to oligomer assembly (1984) (7)
Immunofluorescent localization of transglutaminase in rat small intestine (1988) (6)
Protein polymerizing activity of papain. (1962) (6)
POST‐TRANSLATIONAL PATHWAYS FOR GENERATING ε(γ‐GLUTAMYL)LYSINE CROSS‐LINKS a (1983) (5)
Apparent differences in enzymic rates of hydrolysis of commercial adenosinetriphosphate preparations (1963) (5)
Amide bond cleavage monitored continuously through detection of a dansylcadaverine leaving group. (1992) (4)
Redispersion of actomyosin superprecipitates with the aid of the adenosine triphosphate-creatine transphosphorylase system. (1955) (4)
Transphosphorylating Enzymes and Muscle Relaxation (1959) (4)
Isolation of a polymorphic genomic clone from chromosome 7 (1987) (4)
Transglutaminase-mediated remodeling of the human erythrocyte membrane skeleton: relevance for erythrocyte diseases with shortened cell lifespan. (2011) (3)
RELAXING PARTICLES OF SKELETAL MUSCLE. (1964) (3)
Activation of Human Plasma Factor XIII by Thrombin (1992) (3)
II. 3 – BIOGENESIS OF PROTEIN FIBERS: THE CLOTTING OF BLOOD PLASMA (1959) (3)
Lens transglutaminase and cataract formation [ e-( y-glutamyl ) lysine crosslinks / aging lens / p-crystallins ] (3)
Activation of transglutaminase in mu-calpain null erythrocytes. (2003) (3)
Intermediate filament proteins are targets for crosslinking in the lens by the endogenous transglutaminase (1996) (2)
Ca2+-modulated cross-linking of membrane proteins in intact erythrocytes. (1978) (2)
Biological Functions of Transamidating Enzymes Which Cross-Link Proteins (1977) (2)
Mammalian blood coagulation factors and inhibitors (1993) (2)
Inheritance of factor XIII. (1970) (2)
Deciphering the physiological pathway of clotting of fibrinogen in blood plasma. (2004) (1)
Complement activation, fibrinolysis, and nonmammalian blood coagulation factors and inhibitors (1993) (1)
Radioactivity from 35S-methionine in P. falciparum culture becomes associated with immunoprecipitates specific for erythrocyte membrane proteins. (1984) (1)
Inheritance of Deficiency of Fibrin-stabilizing Factor (Factor XIII) (2006) (1)
[Effect of portal branch ligation on liver regeneration in the rat]. (2000) (1)
14. Structural origins of fibrin clot rigidity (1998) (1)
How do transglutaminases select the reactive lysine residues in their protein substrates (1998) (1)
N epsilon(gamma-glutamyl)lysine crosslinks in the blood clot of the horseshoe crab, Limulus polyphemus. (1992) (1)
Post-translational pathways for generating epsilon(gamma-glutamyl)lysine cross-links. (1983) (1)
On the inactivation of thrombin (1946) (0)
Transglutaminase-specific modifications of crystallins ☆ (1992) (0)
Physiological and Clinical Significance of Disordered Cross-Linking of Fibrin (1977) (0)
TG2 crosslinking of SP1 in ethanol-induced liver injury (2012) (0)
Could intracellular transglutaminases contribute to thrombotic events (1992) (0)
The Effect of Intracellular Transglutaminase on Membrane Structure (1982) (0)
Conserved tryptophan in the transglutaminase is essential catalytic activity (2016) (0)
フィブリノゲン,フィブリンの生理的役割について(スコープ) (1966) (0)
High-pressure liquid chromatographic procedure for the determination of epsilon-(gamma-glutamyl)lysine in proteins. (1982) (0)
Correction. (2019) (0)
Actin and Myosin from Platelets and Muscle are Substrates for Fibrinoligase (1977) (0)
DOWN REGULATION OF PHOSPOLIPASE C EPSILON ACTIVITY BY TRANSGLUTAMINASE 2 IS INDEPENDENT OF ITS CROSS‐LINKING ACTIVITY. (2007) (0)
Inhibition of @-Crystal / in Cross-Linking in the Co 2 +-Treoted Lens (0)
The mechanism of the clotting of fibrinogen with formaldehyde and quinone; interactions between formaldehyde and thrombin. (1948) (0)
Prototypes for Clotting by Transamidation (1977) (0)

This paper list is powered by the following services:

Other Resources About Laszlo Lorand

en.wikipedia.org

What Schools Are Affiliated With Laszlo Lorand?

Laszlo Lorand is affiliated with the following schools:

Laszlo Lorand's Academic­Influence.com Rankings